J&J earnings rise on strong consumer, pharma sales

Share this article:

Johnson & Johnson said its overall earnings increased 9.5% fueled by strong sales from its consumer products division and rising pharmaceutical sales.

J&J pharmaceutical sales were up 7.5% fueled by antipsychotic medication Risperdal, the drugmaker said Tuesday. Meanwhile J&J's consumer-product division saw sales rise 49% backed by a strong performance from Listerine antiseptic mouthwash, the launch of teeth-whitening products and Splenda sweetener among other products.

Johnson & Johnson announced it would purchase Pfizer's consumer healthcare business for $16.6 billion in June 2006, adding brands such as Listerine, Lubriderm, Visine, Neosporin, Sudafed, Zantac and Benadryl to its already lucrative consumer division.

“Consumer is the driving force for J&J, and will be through at least this year,'' said Bruce Cranna, an analyst with Leerink Swann & Co. in an interview with Bloomberg.com.

Johnson & Johnson sales data
(Sales to customers by segment of business)

                                      
                                          2007            2006

Pharmaceutical
US                                   $15,603       $15,092
International                      $9,263         $8,175

Consumer
US                                     $6,408        $4,573
International                      $8,085        $5,201
      
                                            -data provided by Johnson & Johnson

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.